EnGeneIC: US FDA grants fasttrack designation to EnGeneIC's ANDC pancreatic cancer therapeutic
EnGeneIC, an innovative biopharmaceutical company leading the field of armed antibody therapeutics for oncology, has achieved a significant milestone with the granting of FDA 'Fast─Track' designation for its
Read full article »
EnGeneIC is an Australia-based biopharmaceutical company that develops and commercializes therapies for the treatment of cancer and infectious diseases.
Read more